Moleculin Biotech, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
CVI Investments, Inc. and Heights Capital Management, Inc. have jointly filed a Schedule 13G, reporting beneficial ownership of 9.9% of Moleculin Biotech, Inc. common stock.
NASDAQ
Intracoastal Capital LLC, along with individuals Mitchell P. Kopin and Daniel B. Asher, have filed a Schedule 13G, reporting beneficial ownership of 973,927 shares of Moleculin Biotech, Inc. common stock, representing 4.99% of the class.
NASDAQ
Armistice Capital and Steven Boyd updated their beneficial ownership in Moleculin Biotech, Inc., reporting a 4.99% stake.
NASDAQ
Armistice Capital, LLC and its managing member Steven Boyd have reported a beneficial ownership of 8.93% in Moleculin Biotech, Inc., holding 1,250,000 shares of common stock as of March 31, 2025.
NASDAQ
Armistice Capital, LLC and Steven Boyd have disclosed a 9.99% beneficial ownership stake in Moleculin Biotech, Inc. as of December 31, 2024.